Mitochondria-based photodynamic anti-cancer therapy.

PubWeight™: 1.19‹?› | Rank: Top 10%

🔗 View Article (PMID 11377804)

Published in Adv Drug Deliv Rev on July 02, 2001

Authors

J Morgan1, A R Oseroff

Author Affiliations

1: Department of Dermatology, MRC2, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA. janet.morgan@roswellpark.edu

Articles citing this

Mechanisms in photodynamic therapy: part one-photosensitizers, photochemistry and cellular localization. Photodiagnosis Photodyn Ther (2004) 2.47

Mitochondria: pharmacological manipulation of cell death. J Clin Invest (2005) 1.54

Unique diagnostic and therapeutic roles of porphyrins and phthalocyanines in photodynamic therapy, imaging and theranostics. Theranostics (2012) 1.30

Photodynamic therapy and the development of metal-based photosensitisers. Met Based Drugs (2008) 1.24

Low-dose methotrexate enhances aminolevulinate-based photodynamic therapy in skin carcinoma cells in vitro and in vivo. Clin Cancer Res (2009) 1.20

Conjugation of 2-(1'-hexyloxyethyl)-2-devinylpyropheophorbide-a (HPPH) to carbohydrates changes its subcellular distribution and enhances photodynamic activity in vivo. J Med Chem (2009) 1.07

Interaction of cationic meso-porphyrins with liposomes, mitochondria and erythrocytes. J Bioenerg Biomembr (2007) 1.00

Solubilization of poorly soluble PDT agent, meso-tetraphenylporphin, in plain or immunotargeted PEG-PE micelles results in dramatically improved cancer cell killing in vitro. Eur J Pharm Biopharm (2005) 0.88

Novel HPMA copolymer-bound constructs for combined tumor and mitochondrial targeting. Mol Pharm (2008) 0.86

Targeting of mitochondria by 10-N-alkyl acridine orange analogues: role of alkyl chain length in determining cellular uptake and localization. Mitochondrion (2008) 0.85

Structural and physico-chemical determinants of the interactions of macrocyclic photosensitizers with cells. Eur Biophys J (2007) 0.85

Monitoring photosensitizer uptake using two photon fluorescence lifetime imaging microscopy. Theranostics (2012) 0.84

A potent nonporphyrin class of photodynamic therapeutic agent: cellular localisation, cytotoxic potential and influence of hypoxia. Br J Cancer (2005) 0.84

Photosensitizer fluorescence and singlet oxygen luminescence as dosimetric predictors of topical 5-aminolevulinic acid photodynamic therapy induced clinical erythema. J Biomed Opt (2014) 0.83

Electric field-assisted delivery of photofrin to human breast carcinoma cells. J Membr Biol (2013) 0.83

A fiberoptic (photodynamic therapy type) device with a photosensitizer and singlet oxygen delivery probe tip for ovarian cancer cell killing. Photochem Photobiol (2013) 0.82

Enzyme-assisted photosensitization activates different apoptotic pathways in Rose Bengal acetate treated HeLa cells. Histochem Cell Biol (2008) 0.82

Enzyme-assisted photosensitization with rose Bengal acetate induces structural and functional alteration of mitochondria in HeLa cells. Histochem Cell Biol (2006) 0.82

Mitochondria-Targeted Triphenylphosphonium-Based Compounds: Syntheses, Mechanisms of Action, and Therapeutic and Diagnostic Applications. Chem Rev (2017) 0.76

Photosensitizing nanoparticles and the modulation of ROS generation. Front Chem (2015) 0.76

Increased Histone Deacetylase Activity Involved in the Suppressed Invasion of Cancer Cells Survived from ALA-Mediated Photodynamic Treatment. Int J Mol Sci (2015) 0.76

Porphyrin-based cationic amphiphilic photosensitisers as potential anticancer, antimicrobial and immunosuppressive agents. Biophys Rev (2017) 0.75

Synthesis of Tumor-avid Photosensitizer-Gd(III)DTPA conjugates: impact of the number of gadolinium units in T1/T2 relaxivity, intracellular localization, and photosensitizing efficacy. Bioconjug Chem (2010) 0.75

Experimental study on the photodynamic treatment of choroidal neovasculization with nanophthalocyanine photosensitizer. Int J Ophthalmol (2011) 0.75

A next-generation bifunctional photosensitizer with improved water-solubility for photodynamic therapy and diagnosis. Oncotarget (2016) 0.75

Multifunctional 5-aminolevulinic acid prodrugs activating diverse cell-death pathways. Invest New Drugs (2011) 0.75

In vitro and in vivo antitumor activity of a novel porphyrin-based photosensitizer for photodynamic therapy. J Cancer Res Clin Oncol (2015) 0.75

HMME combined with green light-emitting diode irradiation results in efficient apoptosis on human tongue squamous cell carcinoma. Lasers Med Sci (2015) 0.75

Articles by these authors

Resonance Raman spectroscopy of rhodopsin in retinal disk membranes. Biochemistry (1974) 3.19

Rapid-flow resonance Raman spectroscopy of photolabile molecules: rhodopsin and isorhodopsin. Proc Natl Acad Sci U S A (1976) 2.14

Monoclonal antibody therapeutic trials in seven patients with T-cell lymphoma. Blood (1983) 1.39

Antibody-targeted photolysis: selective photodestruction of human T-cell leukemia cells using monoclonal antibody-chlorin e6 conjugates. Proc Natl Acad Sci U S A (1986) 1.36

The cell surface membrane: biochemical aspects and biophysical probes. Annu Rev Biochem (1973) 1.23

Photofrin photodynamic therapy can significantly deplete or preserve oxygenation in human basal cell carcinomas during treatment, depending on fluence rate. Cancer Res (2000) 1.17

Inhibition of lectin agglutinability by fixation of the cell surface membrane. Biochim Biophys Acta (1973) 1.09

The role of transferrin receptor (CD71) in photodynamic therapy of activated and malignant lymphocytes using the heme precursor delta-aminolevulinic acid (ALA). Photochem Photobiol (1995) 1.09

Photosensitization of murine tumor, vasculature and skin by 5-aminolevulinic acid-induced porphyrin. Photochem Photobiol (1995) 1.02

The use of tetrazolium salts to determine sites of damage to the mitochondrial electron transport chain in intact cells following in vitro photodynamic therapy with Photofrin II. Photochem Photobiol (1994) 1.02

Preferential light absorption in atheromas in vitro. Implications for laser angioplasty. J Clin Invest (1986) 1.02

Selective ablation of atheromas using a flashlamp-excited dye laser at 465 nm. Proc Natl Acad Sci U S A (1986) 1.02

Characterization of electric-pulse-induced permeabilization of porcine skin using surface electrodes. Biophys J (1997) 1.01

Intramitochondrial dyes allow selective in vitro photolysis of carcinoma cells. Proc Natl Acad Sci U S A (1986) 0.99

Irradiation of pigmented melanoma cells with high intensity pulsed radiation generates acoustic waves and kills cells. Lasers Surg Med (1990) 0.92

Synthesis of beta-galactose-conjugated chlorins derived by enyne metathesis as galectin-specific photosensitizers for photodynamic therapy. J Org Chem (2001) 0.88

A pulsed electric field enhances cutaneous delivery of methylene blue in excised full-thickness porcine skin. J Invest Dermatol (1998) 0.86

An assay for the quantitation of Photofrin in tissues and fluids. Photochem Photobiol (1997) 0.86

GRP78 induction by calcium ionophore potentiates photodynamic therapy using the mitochondrial targeting dye victoria blue BO. Photochem Photobiol (1998) 0.86

Selective enrichment of human epidermal cell subpopulations using monoclonal antibodies. J Invest Dermatol (1983) 0.86

Photodynamic therapy for the treatment of extramammary Paget's disease. Br J Dermatol (2002) 0.85

IL-10 does not play a role in cutaneous Photofrin photodynamic therapy-induced suppression of the contact hypersensitivity response. Photochem Photobiol (2001) 0.85

A murine monoclonal antibody (VM-1) against human basal cells inhibits the growth of human keratinocytes in culture. J Invest Dermatol (1985) 0.85

Strategies for selective cancer photochemotherapy: antibody-targeted and selective carcinoma cell photolysis. Photochem Photobiol (1987) 0.84

Deletion of alloantigen-activated cells by aminolevulinic acid-based photodynamic therapy. Photochem Photobiol (1999) 0.84

Comparison of photodynamic targets in a carcinoma cell line and its mitochondrial DNA-deficient derivative. Photochem Photobiol (2000) 0.84

Characteristics of the immunosuppression induced by cutaneous photodynamic therapy: persistence, antigen specificity and cell type involved. Photochem Photobiol (2001) 0.82

Expression of the peripheral benzodiazepine receptor is decreased in skin cancers in comparison with normal skin. Br J Dermatol (2004) 0.82

Cytotoxicity and mutagenicity of low intensity, 248 and 193 nm excimer laser radiation in mammalian cells. Cancer Res (1987) 0.81

Mitochondrial toxicity of cationic photosensitizers for photochemotherapy. Cancer Res (1990) 0.81

The anatomic site of photodynamic therapy is a determinant for immunosuppression in a murine model. Photochem Photobiol (1999) 0.81

Laser and photodynamic therapy in the management of cutaneous malignancies. Clin Dermatol (2001) 0.80

Mechanisms of mitochondrial photosensitization by the cationic dye, N,N-bis(2-ethyl-1,3-dioxylene)kryptocyanine (EDKC): preferential inactivation of complex I in the electron transport chain. Cancer Res (1987) 0.80

Design and construction of a light-delivery system for photodynamic therapy. Med Phys (1999) 0.79

Antigen specific and nonspecific modulation of the immune response by aminolevulinic acid based photodynamic therapy. Immunopharmacology (1998) 0.78

Prognostic factors and evaluation of mycosis fungoides and Sézary syndrome. J Am Acad Dermatol (1997) 0.78

Synthesis and evaluation of chalcogenopyrylium dyes as potential sensitizers for the photodynamic therapy of cancer. J Med Chem (1999) 0.78

Antineoplastic activity, synergism, and antagonism of triarylalkylphosphonium salts and their combinations. Anticancer Res (1994) 0.78

pH-dependent chalcogenopyrylium dyes as potential sensitizers for photodynamic therapy: selective retention in tumors by exploiting pH differences between tumor and normal tissue. Photochem Photobiol (1999) 0.77

Characterization of endogenous protoporphyrin IX induced by delta-aminolevulinic acid in resting and activated peripheral blood lymphocytes by four-color flow cytometry. Photochem Photobiol (1998) 0.77

Multiple modality treatment of carcinoma cells with Pt(Rh-123)2 plus x-ray plus light. Photochem Photobiol (1992) 0.77

HTLV-associated diseases: human retroviral infection and cutaneous T-cell lymphomas. Immunol Invest (1997) 0.77

A selenopyrylium photosensitizer for photodynamic therapy related in structure to the antitumor agent AA1 with potent in vivo activity and no long-term skin photosensitization. J Med Chem (2000) 0.76

Water-soluble, core-modified porphyrins as novel, longer-wavelength-absorbing sensitizers for photodynamic therapy. J Med Chem (2000) 0.75

Photosensitizing dyes for the selection of nontumorigenic revertants from human lung cancer cell lines. Cancer Res (1990) 0.75

Immune responses in patients with T-cell lymphoma treated with an anti-idiotype antibody mimicking a highly restricted T-cell antigen. Clin Cancer Res (1995) 0.75

Unscheduled DNA synthesis in human skin after in vitro ultraviolet-excimer laser ablation. J Invest Dermatol (1987) 0.75

Photofrin photodynamic therapy for treatment of AIDS-related cutaneous Kaposi's sarcoma. AIDS (1999) 0.75

Use of a murine monoclonal antibody which binds to malignant keratinocytes to detect tumor cells in microscopically controlled surgery. J Am Acad Dermatol (1983) 0.75

Pleiotropic expression of heterologous cytokine/receptor genes in HTLV-1 associated diseases: candidate TRS for chimeric gene therapy. Leukemia (1997) 0.75

Infrared and laser Raman spectroscopy. Methods Enzymol (1974) 0.75